Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex

G. A. Daniels, Evanthia Galanis

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Intratumoral administration of cytokine genes in order to achieve paracrine secretion of immunostimulatory cytokines and to create tumor vaccines in situ can avoid difficulties associated with the production of autologous and allogeneic vaccines, and toxicity related to systemic administration of cytokines. In this review, we summarize our experience with intratumoral administration of IL-2 cDNA/DMRIE/DOPE lipid complex in patients with metastatic renal cell carcinoma. An objective response rate of 14% was achieved in a phase I/II clinical trial and was confirmed in the low-risk subgroup of a phase II study. The achieved objective clinical responses (PR/CR) were long lasting. Application of PCR and immunohistochemistry in post-treatment tumor biopsies detected the IL-2 plasmid in addition to increased IL-2 expression in tumor cells and CD8 infiltration. Clinical trials employing higher doses of the plasmid in renal cell carcinoma patients with limited disease are ongoing.

Original languageEnglish (US)
Pages (from-to)70-76
Number of pages7
JournalCurrent Opinion in Molecular Therapeutics
Volume3
Issue number1
StatePublished - 2001

Fingerprint

Renal Cell Carcinoma
Immunotherapy
Interleukin-2
Complementary DNA
Cytokines
Lipids
Plasmids
Phase II Clinical Trials
Clinical Trials, Phase I
Cancer Vaccines
Gene Order
Neoplasms
Vaccines
Immunohistochemistry
Clinical Trials
Biopsy
Polymerase Chain Reaction
(3-dimyristyloxypropyl)(dimethyl)(hydroxyethyl)ammonium
Therapeutics

Keywords

  • Gene transfer
  • Human IL-2 gene
  • Liposomes
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{dc6ecfc922164f95aaabdb689c86c537,
title = "Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex",
abstract = "Intratumoral administration of cytokine genes in order to achieve paracrine secretion of immunostimulatory cytokines and to create tumor vaccines in situ can avoid difficulties associated with the production of autologous and allogeneic vaccines, and toxicity related to systemic administration of cytokines. In this review, we summarize our experience with intratumoral administration of IL-2 cDNA/DMRIE/DOPE lipid complex in patients with metastatic renal cell carcinoma. An objective response rate of 14{\%} was achieved in a phase I/II clinical trial and was confirmed in the low-risk subgroup of a phase II study. The achieved objective clinical responses (PR/CR) were long lasting. Application of PCR and immunohistochemistry in post-treatment tumor biopsies detected the IL-2 plasmid in addition to increased IL-2 expression in tumor cells and CD8 infiltration. Clinical trials employing higher doses of the plasmid in renal cell carcinoma patients with limited disease are ongoing.",
keywords = "Gene transfer, Human IL-2 gene, Liposomes, Renal cell carcinoma",
author = "Daniels, {G. A.} and Evanthia Galanis",
year = "2001",
language = "English (US)",
volume = "3",
pages = "70--76",
journal = "Current Opinion in Molecular Therapeutics",
issn = "1464-8431",
publisher = "Current Drugs Ltd.",
number = "1",

}

TY - JOUR

T1 - Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex

AU - Daniels, G. A.

AU - Galanis, Evanthia

PY - 2001

Y1 - 2001

N2 - Intratumoral administration of cytokine genes in order to achieve paracrine secretion of immunostimulatory cytokines and to create tumor vaccines in situ can avoid difficulties associated with the production of autologous and allogeneic vaccines, and toxicity related to systemic administration of cytokines. In this review, we summarize our experience with intratumoral administration of IL-2 cDNA/DMRIE/DOPE lipid complex in patients with metastatic renal cell carcinoma. An objective response rate of 14% was achieved in a phase I/II clinical trial and was confirmed in the low-risk subgroup of a phase II study. The achieved objective clinical responses (PR/CR) were long lasting. Application of PCR and immunohistochemistry in post-treatment tumor biopsies detected the IL-2 plasmid in addition to increased IL-2 expression in tumor cells and CD8 infiltration. Clinical trials employing higher doses of the plasmid in renal cell carcinoma patients with limited disease are ongoing.

AB - Intratumoral administration of cytokine genes in order to achieve paracrine secretion of immunostimulatory cytokines and to create tumor vaccines in situ can avoid difficulties associated with the production of autologous and allogeneic vaccines, and toxicity related to systemic administration of cytokines. In this review, we summarize our experience with intratumoral administration of IL-2 cDNA/DMRIE/DOPE lipid complex in patients with metastatic renal cell carcinoma. An objective response rate of 14% was achieved in a phase I/II clinical trial and was confirmed in the low-risk subgroup of a phase II study. The achieved objective clinical responses (PR/CR) were long lasting. Application of PCR and immunohistochemistry in post-treatment tumor biopsies detected the IL-2 plasmid in addition to increased IL-2 expression in tumor cells and CD8 infiltration. Clinical trials employing higher doses of the plasmid in renal cell carcinoma patients with limited disease are ongoing.

KW - Gene transfer

KW - Human IL-2 gene

KW - Liposomes

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0035126987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035126987&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 70

EP - 76

JO - Current Opinion in Molecular Therapeutics

JF - Current Opinion in Molecular Therapeutics

SN - 1464-8431

IS - 1

ER -